Core Insights - Context Therapeutics Inc. is set to present two posters at the Society for Immunotherapy of Cancer's 40th Annual Meeting, focusing on their T cell engaging bispecific antibodies for solid tumors [1][2] Presentation Details - The first poster will detail a Phase 1 clinical trial of CT-95, a mesothelin x CD3 TCE, scheduled for presentation on November 8, 2025 [3] - The second poster will present preclinical data on CT-202, a Nectin-4 x CD3 TCE, to be showcased on November 7, 2025 [3] Product Information - CT-95 targets mesothelin, a protein overexpressed in approximately 30% of cancers, and aims to minimize the impact of shed MSLN that can interfere with treatment [4] - CT-202 targets Nectin-4, which is overexpressed in various solid tumors, and is designed to be preferentially active in the tumor microenvironment [5] Company Overview - Context Therapeutics is focused on developing T cell engaging bispecific antibodies, including CTIM-76, CT-95, and CT-202, and is headquartered in Philadelphia [6]

PHILADELPHIA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced two posters will be presented at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting, being held November 7–9, 2025, at the Gaylord National Resort and Convention Center in National Harbor, MD. Context’s poster presentations will include a Tri ...

Core Insights - Context Therapeutics Inc. is advancing T cell engaging bispecific antibodies for solid tumors, with a focus on their clinical asset CT-95, which targets mesothelin [1][5] - The company will present data on the first-in-human dose of CT-95 at the AACR Annual Meeting 2025, highlighting the safety of the proposed starting dose of 0.1 μg/kg [2][3] Company Overview - Context Therapeutics is a clinical-stage biopharmaceutical company headquartered in Philadelphia, specializing in T cell engaging bispecific antibodies [5] - The company is developing a portfolio of TCE therapeutics, including CTIM-76, CT-95, and CT-202, targeting various cancer types [5] Product Details - CT-95 is designed to redirect T-cell-mediated lysis towards malignant cells expressing mesothelin, which is overexpressed in approximately 30% of cancers [4] - The product aims to overcome challenges posed by soluble mesothelin fragments that can interfere with MSLN-targeted therapies [4]